CoChat
Sign Up
Cited by 563Cancer Immunotherapy and BiomarkersAngiogenesis and VEGF in CancerLymphatic System and Diseases

Improving immune–vascular crosstalk for cancer immunotherapy

Open access
Huang, Yuhui, Kim, Betty Y. S., Chan, Charles K., Hahn, Stephen M., Weissman, Irving L., Jiang, Wen·2018·Nature Reviews Immunology
DOI 10.1038/nri.2017.145PMC PMC5922422
Open this paper in CoChat — free account

Abstract

The vasculature of tumours is highly abnormal and dysfunctional. Consequently, immune effector cells have an impaired ability to penetrate solid tumours and often exhibit compromised functions. Normalization of the tumour vasculature can enhance tissue perfusion and improve immune effector cell infiltration, leading to immunotherapy potentiation. However, recent studies have demonstrated that the stimulation of immune cell functions can also help to normalize tumour vessels. In this Opinion article, we propose that the reciprocal regulation between tumour vascular normalization and immune reprogramming forms a reinforcing loop that reconditions the tumour immune microenvironment to induce durable antitumour immunity. A deeper understanding of these pathways could pave the way for identifying new biomarkers and developing more effective combination treatment strategies for patients with cancer.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/nri.2017.145

Cites

27 of 27 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Vascular-associated inflammatory readouts are relevant to inflammatory skin pathophysiology.

    “An important feature of the VSA system is its ability to assess vascular-associated inflammatory readouts, which are relevant to inflammatory skin pathophysiology [40][41][42] .”

    From Vascularized human skin assembloids model compartmental skin organization and immune responsiveness in vitro (2026) · cites this paper as [41]

    The “Vessel-based biomarkers for immuno-oncology” section (page unavailable) describes vascular measurements as readouts of changes in the tumour microenvironment during immunotherapy. That supports the general relevance of vascular readouts to immune processes, but the paper does not establish their relevance to inflammatory skin pathophysiology or assess the VSA system. (LLM, conf=0.82)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 104

  1. [1]Burnet FM The concept of immunological surveillance Prog. Exp. Tumor Res 13 1 27 1970 4921480
  2. [2]Burnet M Cancer: a biological approach. III. Viruses associated with neoplastic conditions. IV. Practical applications Br. Med. J 1 841 847 1957 13413231 PMC1973618
  3. [3]Shankaran V IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity Nature 410 1107 1111 2001 11323675
  4. [4]Schreiber RD Old LJ Smyth MJ Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion Science 331 1565 1570 2011 21436444
  5. [5]Khalil DN Smith EL Brentjens RJ Wolchok JD The future of cancer treatment: immunomodulation, CARs and combination immunotherapy Nat. Rev. Clin. Oncol 13 273 290 2016 26977780 PMC5551685
  6. [6]Kalos M T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia Sci. Transl. Med 3 95ra73 2011 PMC3393096 21832238
  7. [7]Porter DL Levine BL Kalos M Bagg A June CH Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia N. Engl. J. Med 365 725 733 2011 21830940 PMC3387277
  8. [8]Eshhar Z Gross G Chimeric T cell receptor which incorporates the anti-tumour specificity of a monoclonal antibody with the cytolytic activity of T cells: a model system for immunotherapeutical approach Br. J. Cancer. Suppl 10 27 29 1990 2383478 PMC2149517
  9. [9]Mayordomo JI Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity Nat. Med 1 1297 1302 1995 7489412
  10. [10]Rosenberg SA Yang JC Restifo NP Cancer immunotherapy: moving beyond current vaccines Nat. Med 10 909 915 2004 15340416 PMC1435696
  11. [11]Schlom J Therapeutic cancer vaccines: current status and moving forward J. Natl. Cancer Inst 104 599 613 2012 22395641 PMC3328421
  12. [12]Madan RA Gulley JL Fojo T Dahut WL Therapeutic cancer vaccines in prostate cancer: the paradox of improved survival without changes in time to progression Oncologist 15 969 975 2010 20798195 PMC3228037
  13. [14]Hodi FS Improved survival with ipilimumab in patients with metastatic melanoma N. Engl. J. Med 363 711 723 2010 20525992 PMC3549297
  14. [16]Reck M Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer N. Engl. J. Med 375 1823 1833 2016 27718847
  15. [17]Nghiem PT PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma N. Engl. J. Med 374 2542 2552 2016 27093365 PMC4927341
  16. [18]Motzer RJ Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma N. Engl. J. Med 373 1803 1813 2015 26406148 PMC5719487
  17. [19]Spitzer MH Systemic Immunity Is Required for Effective Cancer Immunotherapy Cell 168 487 502 2017 28111070 PMC5312823
  18. [20]Ganss R Arnold B Hammerling GJ Mini-review: overcoming tumor-intrinsic resistance to immune effector function Eur. J. Immunol 34 2635 2641 2004 15368278
  19. [21]Motz GT Coukos G Deciphering and reversing tumor immune suppression Immunity 39 61 73 2013 23890064 PMC3782392
  20. [22]Huang Y Goel S Duda DG Fukumura D Jain RK Vascular normalization as an emerging strategy to enhance cancer immunotherapy Cancer Res 73 2943 2948 2013 23440426 PMC3655127
  21. [23]Lanitis E Irving M Coukos G Targeting the tumor vasculature to enhance T cell activity Curr. Opin. Immunol 33 55 63 2015 25665467 PMC4896929
  22. [24]Carmeliet P Jain RK Angiogenesis in cancer and other diseases Nature 407 249 257 2000 11001068
  23. [25]Shweiki D Itin A Soffer D Keshet E Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis Nature 359 843 845 1992 1279431
  24. [26]Kourembanas S Hannan RL Faller DV Oxygen tension regulates the expression of the platelet-derived growth factor-B chain gene in human endothelial cells J. Clin. Invest 86 670 674 1990 2384608 PMC296775
  25. [28]Jain RK Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia Cancer Cell 26 605 622 2014 25517747 PMC4269830
  26. [29]Buckanovich RJ Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy Nat. Med 14 28 36 2008 18157142
  27. [30]Wu NZ Klitzman B Dodge R Dewhirst MW Diminished leukocyte-endothelium interaction in tumor microvessels Cancer Res 52 4265 4268 1992 1638539
  28. [31]Muller WA Mechanisms of leukocyte transendothelial migration Annu. Rev. Pathol 6 323 344 2011 21073340 PMC3628537
  29. [32]Griffioen AW Endothelial intercellular adhesion molecule-1 expression is suppressed in human malignancies: the role of angiogenic factors Cancer Res 56 1111 1117 1996 8640769
  30. [33]Nagarsheth N Wicha MS Zou W Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy Nat. Rev. Immunol 17 559 572 2017 28555670 PMC5731833
  31. [34]Tang H Facilitating T Cell Infiltration in Tumor Microenvironment Overcomes Resistance to PD-L1 Blockade Cancer Cell 29 285 296 2016 26977880 PMC4794755
  32. [35]Jiang W Chan CK Weissman IL Kim BYS Hahn SM Immune Priming of the Tumor Microenvironment by Radiation Trends Cancer 2 I638 645 2016 28741502
  33. [36]Jiang H Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy Nat. Med 22 851 860 2016 27376576 PMC4935930
  34. [39]Qian BZ Pollard JW Macrophage diversity enhances tumor progression and metastasis Cell 141 39 51 2010 20371344 PMC4994190
  35. [40]Gabrilovich DI Ostrand-Rosenberg S Bronte V Coordinated regulation of myeloid cells by tumours Nat. Rev. Immunol 12 253 268 2012 22437938 PMC3587148
  36. [41]Curiel TJ Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival Nat. Med 10 942 949 2004 15322536
  37. [42]Facciabene A Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and T(reg) cells Nature 475 226 230 2011 21753853
  38. [43]Doedens AL Macrophage expression of hypoxia-inducible factor-1 alpha suppresses T-cell function and promotes tumor progression Cancer Res 70 7465 7475 2010 20841473 PMC2948598
  39. [44]Klages K Selective depletion of Foxp3+ regulatory T cells improves effective therapeutic vaccination against established melanoma Cancer Res 70 7788 7799 2010 20924102
  40. [46]Zhou Y PD-1 and PD-L1 expression in 132 recurrent nasopharyngeal carcinoma: the correlation with anemia and outcomes Oncotarget 8 51210 51223 2017 28881642 PMC5584243
  41. [48]Koh J EML4-ALK enhances programmed cell death-ligand 1 expression in pulmonary adenocarcinoma via hypoxia-inducible factor (HIF)-1alpha and STAT3 Oncoimmunology 5 e1108514 2016 27141364 PMC4839370
  42. [52]Sitkovsky MV Kjaergaard J Lukashev D Ohta A Hypoxia-adenosinergic immunosuppression: tumor protection by T regulatory cells and cancerous tissue hypoxia Clin. Cancer Res 14 5947 5952 2008 18829471
  43. [53]Fischer K Inhibitory effect of tumor cell-derived lactic acid on human T cells Blood 109 3812 3819 2007 17255361
  44. [55]Huber V Cancer acidity: An ultimate frontier of tumor immune escape and a novel target of immunomodulation Semin. Cancer Biol 43 74 89 2017 28267587
  45. [56]Mendler AN Tumor lactic acidosis suppresses CTL function by inhibition of p38 and JNK/c-Jun activation Int. J. Cancer 131 633 640 2012 21898391
  46. [58]Jiang W Huang Y An Y Kim BYS Remodeling Tumor Vasculature to Enhance Delivery of Intermediate-Sized Nanoparticles ACS Nano 9 8689 8696 2015 26212564
  47. [59]Hamzah J Vascular normalization in Rgs5-deficient tumours promotes immune destruction Nature 453 410 414 2008 18418378
  48. [60]Liu Y Regulation of leukocyte transmigration: cell surface interactions and signaling events J. Immunol 172 7 13 2004 14688302
  49. [61]Huang Y Stylianopoulos T Duda DG Fukumura D Jain RK Benefits of vascular normalization are dose and time dependent Cancer Res 73 7144 6 2013 24265277 PMC3876035
  50. [62]Shrimali RK Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer Cancer Res 70 6171 6180 2010 20631075 PMC2912959
  51. [63]Huang Y Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy Proc. Natl. Acad. Sci. U.S.A 109 17561 17566 2012 23045683 PMC3491458
  52. [66]Hatfield SM Immunological mechanisms of the antitumor effects of supplemental oxygenation Sci. Transl. Med 7 277ra230 2015 PMC4641038 25739764
  53. [67]Mazzieri R Targeting the ANG2/TIE2 axis inhibits tumor growth and metastasis by impairing angiogenesis and disabling rebounds of proangiogenic myeloid cells Cancer Cell 19 512 526 2011 21481792
  54. [68]Hashizume H Complementary actions of inhibitors of angiopoietin-2 and VEGF on tumor angiogenesis and growth Cancer Res 70 2213 2223 2010 20197469 PMC2840050
  55. [69]Peterson TE Dual inhibition of Ang-2 and VEGF receptors normalizes tumor vasculature and prolongs survival in glioblastoma by altering macrophages Proc. Natl. Acad. Sci. U.S.A 113 4470 4475 2016 27044097 PMC4843449
  56. [74]Carretero R Eosinophils orchestrate cancer rejection by normalizing tumor vessels and enhancing infiltration of CD8(+) T cells Nat. Immunol 16 609 617 2015 25915731
  57. [76]Curran MA Montalvo W Yagita H Allison JP PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors Proc. Natl. Acad. Sci. U.S.A 107 4275 4280 2010 20160101 PMC2840093
  58. [78]Leach DR Krummel MF Allison JP Enhancement of antitumor immunity by CTLA-4 blockade Science 271 1734 1736 1996 8596936
  59. [80]Kamphorst AO Rescue of exhausted CD8 T cells by PD-1-targeted therapies is CD28-dependent Science 355 1423 1427 2017 28280249 PMC5595217
  60. [81]Huang AC T-cell invigoration to tumour burden ratio associated with anti-PD-1 response Nature 545 60 65 2017 28397821 PMC5554367
  61. [82]Ruegg C Evidence for the involvement of endothelial cell integrin alphaVbeta3 in the disruption of the tumor vasculature induced by TNF and IFN-gamma Nat. Med 4 408 414 1998 9546785
  62. [83]Beatty GL Paterson Y IFN-γ-Dependent Inhibition of Tumor Angiogenesis by Tumor-Infiltrating CD4+ T Cells Requires Tumor Responsiveness to IFN-γ J. Immunol 166 2276 2282 2001 11160282
  63. [84]Hayakawa Y IFN-gamma-mediated inhibition of tumor angiogenesis by natural killer T-cell ligand, alpha-galactosylceramide Blood 100 1728 33 2002 12176894
  64. [85]Ohm JE VEGF inhibits T-cell development and may contribute to tumor-induced immune suppression Blood 101 4878 86 2003 12586633
  65. [86]Gabrilovich DI Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells Nat. Med 2 1096 1103 1996 8837607
  66. [87]Huang Y Resuscitating cancer immunosurveillance: selective stimulation of DLL1-Notch signaling in T cells rescues T-cell function and inhibits tumor growth Cancer Res 71 6122 6131 2011 21825014 PMC3185141
  67. [88]Huang Y Distinct roles of VEGFR-1 and VEGFR-2 in the aberrant hematopoiesis associated with elevated levels of VEGF Blood 110 624 631 2007 17376891 PMC1924481
  68. [89]Romagnani P Lasagni L Annunziato F Serio M Romagnani S CXC chemokines: the regulatory link between inflammation and angiogenesis Trends Immunol 25 201 209 2004 15039047
  69. [90]Arenberg DA Interferon-gamma-inducible protein 10 (IP-10) is an angiostatic factor that inhibits human non-small cell lung cancer (NSCLC) tumorigenesis and spontaneous metastases J. Exp. Med 184 981 992 1996 9064358 PMC2192788
  70. [91]Fathallah-Shaykh HM Zhao LJ Kafrouni AI Smith GM Forman J Gene transfer of IFN-gamma into established brain tumors represses growth by antiangiogenesis J. Immunol 164 217 222 2000 10605014
  71. [92]Kammertoens T Tumour ischaemia by interferon-gamma resembles physiological blood vessel regression Nature 545 98 102 2017 28445461 PMC5567674
  72. [94]Peng D Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy Nature 527 249 253 2015 26503055 PMC4779053
  73. [95]Spranger S Bao R Gajewski TF Melanoma-intrinsic beta-catenin signalling prevents anti-tumour immunity Nature 523 231 235 2015 25970248
  74. [96]Murdoch C Muthana M Coffelt SB Lewis CE The role of myeloid cells in the promotion of tumour angiogenesis Nat. Rev. Cancer 8 618 631 2008 18633355
  75. [97]Yang L Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis Cancer Cell 6 409 421 2004 15488763
  76. [98]Lewis CE Harney AS Pollard JW The multifaceted role of perivascular macrophages in tumors Cancer Cell 30 18 25 2016 27411586 PMC5024543
  77. [100]Huang S Contributions of stromal metalloproteinase-9 to angiogenesis and growth of human ovarian carcinoma in mice J. Natl Cancer Inst 94 1134 1142 2002 12165638
  78. [101]Huang Y Snuderl M Jain RK Polarization of tumor-associated macrophages: a novel strategy for vascular normalization and antitumor immunity Cancer Cell 19 1 2 2011 21251607 PMC3037265
  79. [104]Rigamonti N Role of Angiopoietin-2 in Adaptive Tumor Resistance to VEGF Signaling Blockade Cell Rep 8 696 706 2014 25088418
  80. [105]Goede V Identification of serum angiopoietin-2 as a biomarker for clinical outcome of colorectal cancer patients treated with bevacizumab-containing therapy Br. J. Can 103 1407 1414 2010 PMC2990609 20924372
  81. [106]De Palma M Naldini L Angiopoietin-2 TIEs up macrophages in tumour angiogenesis Clin. Cancer Res 17 5226 32 2011 21576085
  82. [107]Wu W Angiopoietin-2 as a Biomarker and Target for Immune Checkpoint Therapy Can. Immunol. Res 5 17 28 2017 PMC5215959 28003187
  83. [108]Piesche M Angiogenic cytokines are antibody targets during graft-versus-leukemia reactions Clin. Cancer Res 21 1010 8 2015 25538258 PMC4348150
  84. [109]Schoenfeld J Active immunotherapy induces antibody responses that target tumor angiogenesis Cancer Res 70 10150 10160 2010 21159637 PMC3057563
  85. [110]Zahra MA Dynamic contrast-enhanced MRI as a predictor of tumour response to radiotherapy Lancet Oncol 8 63 74 2007 17196512
  86. [111]Padhani AR Miles KA Multiparametric Imaging of Tumor Response to Therapy Radiology 256 348 364 2010 20656830
  87. [112]Martinet L Human solid tumors contain high endothelial venules: association with T- and B-lymphocyte infiltration and favorable prognosis in breast cancer Cancer Res 71 5678 87 2011 21846823
  88. [113]Twyman-Saint Victor C Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer Nature 520 373 377 2015 25754329 PMC4401634
  89. [114]Vanneman M Dranoff G Combining immunotherapy and targeted therapies in cancer treatment Nat. Rev. Cancer 12 237 251 2012 22437869 PMC3967236
  90. [115]Gotwals P Prospects for combining targeted and conventional cancer therapy with immunotherapy Nat. Rev. Cancer 17 286 301 2017 28338065
  91. [116]Kang J Demaria S Formenti S Current clinical trials testing the combination of immunotherapy with radiotherapy J. Immunother. Cancer 4 51 70 2016 27660705 PMC5028964
  92. [117]Bernstein MB Krishnan S Hodge JW Chang JY Immunotherapy and stereotactic ablative radiotherapy (ISABR): a curative approach? Nat. Rev. Clin. Oncol 13 516 524 2016 26951040 PMC6053911
  93. [118]Demaria S Coleman CN Formenti SC Radiotherapy: Changing the Game in Immunotherapy Trend Cancer 2 286 294 2016 PMC5070800 27774519
  94. [119]Jiang W Chan CK Weissman IL Kim BYS Hahn SM Immune Priming of the Tumor Microenvironment by Radiation Trend Cancer 2 638 645 2016 28741502
  95. [120]Klug F Low-dose irradiation programs macrophage differentiation to an iNOS+/M1 phenotype that orchestrates effective T cell immunotherapy Cancer Cell 24 589 602 2013 24209604
  96. [121]De Palma M Coukos G Hanahan D A new twist on radiation oncology: low-dose irradiation elicits immunostimulatory macrophages that unlock barriers to tumor immunotherapy Cancer Cell 24 559 61 2013 24229704
  97. [122]Filatenkov A Ablative tumor radiation can change the tumor immune cell microenvironment to induce durable complete remissions Clin. Cancer Res 21 3727 3739 2015 25869387 PMC4537844
  98. [124]Jain RK Tong RT Munn LL Effect of vascular normalization by antiangiogenic therapy on interstitial hypertension, peritumor edema, and lymphatic metastasis: Insights from a mathematical model Cancer Res 67 2729 2735 2007 17363594 PMC3022341
  99. [125]Jain RK Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia Cancer Cell 26 605 622 2014 25517747 PMC4269830
  100. [126]Lund AW Rethinking Lymphatic Vessels and Antitumor Immunity Trend Cancer 2 548 551 2016 28741486
  101. [127]Rotin D Robinson B Tannock IF Influence of hypoxia and an acidic environment on the metabolism and viability of cultured cells: potential implications for cell death in tumors Cancer Res 46 2821 2826 1986 3698008
  102. [128]Eil R Ionic immune suppression within the tumour microenvironment limits T cell effector function Nature 537 539 543 2016 27626381 PMC5204372
  103. [129]Maj T Oxidative stress controls regulatory T cell apoptosis and suppressor activity and PD-L1-blockade resistance in tumour Nat. Immunol 10.1038/ni.3868 2017 PMC5770150 29083399 · DOI · Paper page
  104. [130]Tang H Qiao J Fu YX Immunotherapy and tumor microenvironment Cancer Lett 370 85 90 2016 26477683 PMC4725050

Cited by

Sorted by citations

Authors
Huang, Y., Kim, B. Y. S., Chan, C. K., Hahn, S. M., Weissman, I. L., & Jiang, W.
Affiliations
  • Soochow University (CN)
  • Mayo Clinic (US)
  • Stanford Medicine (US)
  • The University of Texas MD Anderson Cancer Center (US)
Corresponding author
  • Huang, Yuhui
  • Kim, Betty Y. S.
  • Jiang, Wen
ORCID
Venue
Nature Reviews Immunology
Publisher
Springer Science and Business Media LLC
Published
2018-01-15
Volume
18
Issue
3
Pages
195-203
ISSN
  • 1474-1733 (ISSN-L)
  • 1474-1741
DOI
10.1038/nri.2017.145
PMC
PMC5922422
OpenAlex
W2783703728
Cited by
563
References
27
Citations by year
2026: 70 · 2025: 81 · 2024: 85 · 2023: 77 · 2022: 88 · 2021: 61 · 2020: 60 · 2019: 27 · 2018: 13
FWCI
4.23
Type
journal article
Language
en
Open access
Licence
www.springer.com/tdm (tdm)
Locations
  • Nature reviews. Immunology (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • National Cancer Institute (R35CA220434)
  • National Institute of Neurological Disorders and Stroke (R01NS104315)
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
  • Health Sciences › Medicine › Oncology › Lymphatic System and Diseases
Keywords
cancer immunotherapy, tumor immune microenvironment, immune reprogramming, positive feedback loop, antitumor immunity, tissue perfusion, biomarkers, combination therapy
MeSH terms
Humans, Neoplasms, Neovascularization, Pathologic, T-Lymphocytes, Immunotherapy, Adoptive, Tumor Microenvironment

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review